Co-Diagnostics, Inc. Common Stock Cash Flow Conversion Efficiency
Co-Diagnostics, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has a cash flow conversion efficiency ratio of -0.489x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($16.04 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Co-Diagnostics, Inc. Common Stock (2014–2025)
Cash flow conversion efficiency of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. This chart illustrates how Co-Diagnostics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Co-Diagnostics, Inc. Common Stock stock price today for real-time trading data and today's change.
Co-Diagnostics, Inc. Common Stock Cash Flow Conversion Ratio Explained
Co-Diagnostics, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Co-Diagnostics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see Co-Diagnostics, Inc. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Xaar plc
LSE:XAR
|
-0.059x |
|
Condmag Brasov
RO:COMI
|
0.067x |
|
Beyon 3D Ltd
TA:BYON
|
N/A |
|
RED LAKE GOLD INC.
F:P11A
|
-1.043x |
|
Savannah Energy PLC
LSE:SAVE
|
0.060x |
|
GO2 People Ltd
AU:GO2
|
-0.007x |
|
Pineapple Financial Inc.
NYSE:PAPL
|
0.471x |
|
Anatara Lifesciences Ltd
AU:ANR
|
-2.561x |
Annual Cash Flow Conversion Efficiency for Co-Diagnostics, Inc. Common Stock (2014–2025)
The table below shows the annual cash flow conversion efficiency of Co-Diagnostics, Inc. Common Stock from 2014 to 2025. Review Co-Diagnostics, Inc. Common Stock free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $20.63 Million | $-29.14 Million | -1.412x | -163.12% |
| 2024-12-31 | $54.31 Million | $-29.16 Million | -0.537x | -109.10% |
| 2023-12-31 | $86.01 Million | $-22.08 Million | -0.257x | -547.58% |
| 2022-12-31 | $114.52 Million | $6.57 Million | 0.057x | -81.22% |
| 2021-12-31 | $134.48 Million | $41.08 Million | 0.305x | -27.66% |
| 2020-12-31 | $66.70 Million | $28.17 Million | 0.422x | +113.28% |
| 2019-12-31 | $1.74 Million | $-5.53 Million | -3.180x | -182.53% |
| 2018-12-31 | $-1.06 Million | $-4.08 Million | 3.853x | +562.03% |
| 2017-12-31 | $3.85 Million | $-3.21 Million | -0.834x | -290.32% |
| 2016-12-31 | $-2.99 Million | $-1.31 Million | 0.438x | -67.15% |
| 2015-12-31 | $-1.15 Million | $-1.53 Million | 1.334x | +119.98% |
| 2014-12-31 | $138.63K | $-925.23K | -6.674x | -- |
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more